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The Shiga toxins of Shiga toxin-producing Escherichia 
coli (STEC) can be divided into Shiga toxin 1 (Stx1) and 
Shiga toxin 2 (Stx2) with several sub-variants. Variant 
Stx2f is one of the latest described, but has been rarely 
associated with symptomatic human infections. In the 
enhanced STEC surveillance in the Netherlands, 198 
STEC O157 cases and 351 STEC non-O157 cases, includ-
ing 87 stx2f STEC isolates, were reported between 
2008 and 2011. Most stx2f strains belonged to the 
serogroups O63:H6 (n=47, 54%), O113:H6 (n=12, 14%) 
and O125:H6 (n=12, 14%). Of the 87 stx2f isolates, 84 
(97%) harboured the E. coli attaching and effacing 
(eae) gene, but not the enterohaemorrhagic E. coli hae-
molysin (hly) gene. stx2f STEC infections show milder 
symptoms and a less severe clinical course than STEC 
O157 infections. Almost all infections with stx2f (n=83, 
95%) occurred between June and December, compared 
to 170/198 (86%) of STEC O157 and 173/264 (66%) 
of other STEC non-O157. stx2f STEC infections in the 
Netherlands are more common than anticipated, and 
form a distinct group within STEC with regard to viru-
lence genes and the relatively mild disease.
Introduction 
Shiga toxin-producing Escherichia coli (STEC) is an 
important pathogen worldwide, associated with 
human illness, most notably diarrhoea, bloody diar-
rhoea, haemorrhagic colitis, and haemolytic uraemic 
syndrome (HUS) [1,2]. Ruminants, especially cattle, are 
considered the main reservoir for STEC, from where it 
spreads to humans by contaminated food and/or water. 
A broad range of virulence factors is associated with the 
severity of STEC infection [3]. Shiga toxin is an essen-
tial factor for the development of severe symptoms like 
HUS and can be divided into two main types: Shiga 
toxin 1 (Stx1) and Shiga toxin 2 (Stx2). Within both 
groups, several variants are distinguished. Variant stx2f 
is one of the latest described in the literature, found 
in E. coli strains from pigeons [4-7]. So far, reports 
of human illness due to stx2f  STEC are scarce [5,8,9]. 
Stx2f  genes were present in only one of 62 isolates of 
STEC non-O157 cases in the United Kingdom between 
1983 and 2000 [10], but was not found in 530 isolates 
of STEC non-O157 cases in Germany in the period from 
1996 to 2000 [11]. Prager et al. [12] presented data from 
32 stx2f STEC cases identified between 2004 and 2007 
in Germany, suggesting that this might be an emerging 
pathogen. In Japan, between 1996 and 2006, 24 cases 
with a rare STEC non-O157 serogroup infection were 
tested for stx2f, yielding two cases [9]. Furthermore, 
two relatives of these cases were found to be asymp-
tomatic stx2f  STEC carriers. During a multi-centre study 
in the Netherlands (2005–2006), isolates of 21 STEC 
cases were tested for stx2f of which three (14%) tested 
positive, which, at that time, was already higher than 
expected based on the previous international reports 
[13].
In the Netherlands, STEC isolates are submitted to the 
National Institute for Public Health and the Environment 
(RIVM) for confirmation and further typing. Since 2007, 
submitted strains have been routinely tested for stx2f. 
This lead to the observation that stx2f STEC was rela-
tively common. The question was raised whether stx2f 
STEC cases had distinct clinical and epidemiological 
characteristics compared to other STEC cases.
Methods
Since January 1999, an enhanced surveillance of STEC 
O157 has been implemented in the Netherlands. STEC 
became notifiable in the same year, effectively being 
STEC O157. In 2007, STEC non-O157 has been added to 
the enhanced surveillance, which effectively started 
running in 2008. The notifications of STEC non-O157 do 
not cover the whole country, as only a fraction of the 
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laboratories use molecular methods for the detection 
of all STEC, although the number of laboratories capa-
ble of doing this is rising. All medical microbiological 
laboratories in the Netherlands have to report a posi-
tive result for STEC to the local public health service. In 
addition, they can voluntarily send up to five isolates 
per patient to the RIVM for confirmation, free of charge. 
Putative STEC colonies are tested by polymerase chain 
reaction (PCR) for the presence of the Shiga toxin 1 
(stx1), Shiga toxin 2 (stx2), E. coli attaching and effacing 
(eae) and enterohaemorrhagic E. coli haemolysin (hly) 
genes using primers as described by Paton et al. [14]. 
The presence of stx2f is tested with the PCR method as 
described by Schmidt et al. [4]. If stx-positive colonies 
are detected, O- and H-typing are performed [15,16]. 
The regional public health services gather information 
about age, sex, symptoms and date of illness onset of 
each case as part of the notification. In the enhanced 
surveillance, regional public health services are also 
asked to complete a more elaborate questionnaire 
together with the case about the clinical manifesta-
tion and possible risk factors, such as food consump-
tion, and outdoor activities in the week before date of 
onset. Cases with a STEC infection and an isolate con-
firmed and typed at the RIVM between January 2008 
and December 2011 were included in the current analy-
sis. In this period, one national outbreak of STEC O157 
(n=19 cases) and the German outbreak of STEC O104 
(n=11 cases) were identified [17,18]. Cases linked to 
these outbreaks were excluded.
Since 2008, a control survey in the general popula-
tion has been added in the Netherlands; three times 
a year, a questionnaire intended for all age groups is 
sent to a sample of the general population, containing 
similar questions as used for cases with notifiable gas-
troenteritis pathogens and respiratory infections about 
health and underlying diseases, food consumption, 
and outdoor activities. This survey is set up to deter-
mine risk factors for these diseases, including trends 
through the years; the survey can also be helpful in 
investigations of outbreaks caused by these pathogens 
and infections, especially when an outbreak is diffuse 
in space and/or time. Between July 2008 and December 
2011, 3,908 control questionnaires were mailed and 
1,420 were returned (overall response of 36.3%). 
Stx2f STEC was compared with other STEC, divided 
into STEC O157 and STEC non-O157, regarding O type 
and presence of other genes, age and symptoms of 
the cases, and risk factors. Differences were tested 
using the chi-squared test (with p<0.05 considered sig-
nificant). A similar comparison was done between stx2f 
STEC cases and controls concerning the risk factors, 
extended with a logistic regression analysis to calcu-
late adjusted odds ratios. 
Results
Between 2008 and 2011, a total of 549 STEC cases 
were reported for which the STEC could be isolated 
and typed, resulting in 198 O157 infections and 351 
non-O157 infections (Table 1). The steady rise of STEC 
non-O157 infections over time is most likely due to 
the increasing number of laboratories using PCR-
techniques to identify all STEC infections. A quarter 
(n=87) of the 351 STEC non-O157 isolates contained the 
stx2f gene. None of the STEC O157 isolates contained 
the stx2f variant. Of the 87 stx2f isolates, 84 (97%) har-
boured the eae gene, but not the hly gene. The remain-
ing three contained neither eae nor hly. For the other 
264 STEC non-O157 isolates, this was six (2%) with eae 
but not hly and 83 (31%) with neither eae nor hly. All 
198 STEC O157 isolates contained hly and all but one 
isolate eae. 
Table 1
Shiga toxin genes (stx) in human STEC non-O157 (n=351) and O157 (n=198) isolates, the Netherlands, 2008–2011
Type 2008 2009 2010 2011 Total
STEC non-O157 total 45 51 81 174 351
Stx1
a n(%) 14 (31) 25 (49) 31 (38) 70 (40) 140 (40)
Stx2
b n(%) 16 (36) 11 (22) 16 (20) 41 (24) 84 (24)
Stx1+stx2 n(%) 5 (11) 4 (8) 12 (15) 19 (11) 40 (11)
Stx2f
c n(%) 10 (22) 11 (22) 22 (27) 44 (25) 87 (25)
STEC O157 total 45 38 50 65 198
Stx1
a n(%) 0 (0) 1 (3) 1 (2) 0 (0) 2 (1)
Stx2
b n(%) 18 (40) 17 (45) 17 (34) 19 (29) 71 (36)
Stx1+stx2 n(%) 27 (60) 20 (53) 32 (64) 46 (71) 125 (63)
Stx2f
c n(%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
STEC: Shiga toxin-producing Escherichia coli.
a  Stx1 was found but not stx2 in these isolates.
b  Stx2 was found but not stx1 in these isolates.
c  In these isolates stx2f was found but not stx1 or other stx2.
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Besides STEC O-non-typable, 65 different STEC non-
O157 O-types were found between 2008 and 2011, of 
which 11 O-types were also seen with the stx2f gene 
(Table 2). Especially O63:H6 was related to stx2f, fol-
lowed by O113:H6 and O125:H6.
Ninety five per cent of the stx2f STEC infections (83/87) 
occurred between June and December (Figure). STEC 
O157 infections also show a seasonal trend, although 
somewhat less pronounced, with 170/198 (86%) 
between June and December. No clear seasonal trend 
is seen in the other STEC non-O157 infections (June–
December: 173/264; 66%). 
The median age of cases with a stx2f STEC infection was 
31 years, compared to 28 years for cases with another 
STEC non-O157 infection and 21 years for cases with 
an STEC O157 infection (Table 3). The differences in 
median age and age distribution were not statistically 
significant, although O157 cases tended to be younger. 
Cases with an stx2f STEC infection had significantly less 
frequently blood in the stool than STEC O157 cases 
(p<0.0001) and a smaller proportion had problems with 
low production of urine during the infection than for 
cases of STEC O157 (p<0.0001) and non-O157 (p=0.03) 
(Table 3). Furthermore, stx2f STEC cases had less fre-
quently stomach ache (p<0.0001), were reported with 
no HUS (p=0.049) and were less frequently hospital-
ised (p=0.001) compared to STEC O157 cases. The per-
centages of stx2f STEC cases with such characteristics 
were however similar to those in the other non-O157 
STEC cases. None of the stx2f STEC cases died due to 
the infection, compared to one of 224 other STEC non-
O157 cases (0.4%) and two of 186 STEC O157 cases (1%) 
for which the information was known.
Cases with a stx2f STEC infection less frequently 
reported having had contact with someone with gastro-
intestinal complaints in the week before illness onset 
than the other STEC non-O157 (p=0.030) and STEC 
O157 cases (p=0.046; Table 4). On the other hand, 
the stx2f STEC cases more frequently reported having 
eaten dairy products made of raw milk (p=0.010) or 
bean sprouts (p=0.018) than STEC O157 cases. The dif-
ference in consumption of bean sprouts between stx2f 
cases and other STEC non-O157 cases was close to sig-
nificance (0.055). Bean sprouts were also eaten more 
often by stx2f cases compared to the controls; the odds 
ratio for consumption of bean sprouts was 2.3 (95% 
confidence interval: 1.1–5.1), adjusted for age, sex 
and urbanisation level. No specific questions about 
contact with birds were included in the questionnaire, 
except for owning poultry, but it could be reported in 
open questions addressing contact with animals. None 
of the 31 stx2f STEC cases reported contact with birds, 
compared to six (6%) and nine (7%) of the other 98 
STEC non-O157 and the 135 STEC O157 cases for which 
the information was known, respectively.
Discussion
Between 2008 and 2011, stx2f STEC infections com-
prised 25% of all STEC non-O157 infections in this 
period and 16% of all STEC isolated. Excluding the labo-
ratories unable to detect all STEC infections, stx2f STEC 
infections constitute 20% of all STEC infections. This 
is clearly higher than reported before [9,10,12]. Within 
a Dutch multi-centre study between 2005 and 2006, 
three (14%) of 21 STEC cases tested, were positive for 
stx2f, which was already higher than earlier reports 
[13]. As these studies all were done before 2008, the 
relative high percentage in the present study could 
be a sign that stx2f STEC is emerging. In Belgium, the 
percentage stx2f STEC was 13% (all STEC) or 17% (STEC 
non-O157) over the period from 2008 to 2010 [19]. The 
low frequency of internationally reported human stx2f 
STEC infections may be due to the mild course of the 
disease and due to underdiagnosis, as several STEC 
assays targeting stx (genes) are not capable of detect-
ing the stx2f variant. For example, standard PCR assays 
and GeneDisc real-time PCR do not detect stx2f [20-
22], but requires a specific primer/probe design [21]. 
Beutin et al. [23] tested two enzyme immunoassays, 
of which P1-glycoprotein-enzyme immunoassay (EIA) 
could not and Ridascreen-EIA could detect stx2f. The 
seemingly mild disease caused by stx2f STEC infections 
does not stimulate adjusting the commonly used tech-
niques which, in turn, enhances underdiagnosis and 
underreporting. To be certain however, that stx2f STEC 
Table 2
STEC serotypes (n=11) found to contain the Shiga toxin 2f 
gene (stx2f), the Netherlands, 2008–2011






















STEC: Shiga toxin-producing Escherichia coli.
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Figure 
Seasonal distribution of stx2f STEC (non-O157) cases (n=87), other STEC non-O157 cases (n=264) and STEC O157 cases 
(n=198), the Netherlands, 2008–2011



























Reported clinical data of the Shiga toxin-producing Escherichia coli (STEC) cases, the Netherlands, 2008–2011 (n=549)





Median age in years (minimum–maximum) 31 (0–90) 28 (0–92) 21 (0–85)
Age groups
0–4 years 17/87 (20) 41/264 (16) 40/198 (20)
5–19 years 15/87 (17) 58/264 (22) 52/198 (26)
20–39 years 17/87 (20) 63/264 (24) 46/198 (23)
40–59 years 20/87 (23) 46/264 (17) 30/198 (15)
>60 years 18/87 (21) 56/264 (21) 30/198 (15)
Sex, % male 41/85 (48) 99/259 (38) 75/198 (38)
Diarrhoea 53/60 (88) 156/179 (87) 164/173 (95)
Stomach ache 36/60 (60) 126/178 (71) 151/172 (88)b
Blood in stool 9/60 (15) 47/178 (26) 132/173 (76)b
Less urine production 2/59 (3) 24/176 (14)b 49/170 (29)b
HUS 0/63 (0) 4/191 (2) 11/182 (6)b
Hospitalisation 9/58 (16) 29/175 (17) 73/177 (41)b
Deceased 0/72 (0) 1/224 (0) 2/186 (1)
HUS: haemolytic uraemic syndrome.
In the Table the denominators of the fractions vary because the information in question was not available from all cases.
a Fractions and the resulting percentages are given unless otherwise specified.
b Significantly different from stx2f cases (p<0.05).
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infections are in fact generally mild, more testing and 
research is needed.
Almost all stx2f isolates possessed the eae gene, which 
was also reported for the stx2f isolates found in pigeons 
[7] and in earlier reports of human stx2f STEC infections 
[9,12]. None of the stx2f isolates contained the hly gene, 
as was also reported by Prager et al. [12] and Seto et 
al. [9]. The combination of the presence of the eae gene 
but absence of the hly gene is rarely seen in the other 
(non-stx2f) STEC non-O157 infections and not seen at all 
in STEC O157 infections within the Dutch STEC surveil-
lance. The absence of a finding in this study of a single 
isolate with a stx2f gene together with a stx1 gene and 
the fact that this combination is not reported in the lit-
erature so far suggests that stx2f isolates form a dis-
tinct group within the STEC infections.
Escherichia albertii has recently been identified as 
eae-positive Escherichia, including stx2f strains [24-27]. 
The stx2f strains were isolated from a patient with diar-
rhoea and from a healthy crow-like bird [27]. Due to 
those characteristics, E. albertii strains might be misi-
dentified as enterohaemorrhagic E. coli (EHEC) or STEC. 
E. albertii and E. coli are strongly related and are dif-
ficult to discriminate based on 16S sequence (data not 
shown). Nine isolates in the present study were specifi-
cally tested for the inability to ferment lactose, which 
is a phenotypic trait discriminating E. albertii from 
E. coli [27]. Based on this biochemical test all nine tested 
isolates belonging to the present study appeared to be 
E. coli. However, this does not entirely exclude the pos-
sibility that part of the remaining isolates is E. albertii 
instead of E. coli. 
In the period from 2008 to 2011, the stx2f isolates ana-
lysed in this study, belonged to 11 O-types, with four 
O-types accounting for 87%. O63:H6, appears to be 
most often associated with stx2f, based on this study 
and previous reports [9,12,13]. Also, the association 
with serotype O132:H34 has been reported before [12]. 
O113:H6, O125:H6 and the more rare O-types of the 
stx2f isolates have not been related to stx2f before. None 
of the serogroups found in the current study have been 
reported in pigeons or other birds [4,7].
Preliminary results from a molecular risk assessment 
study (data not shown) included five O63 strains and 
these were all found to harbour relatively low numbers 
of additional STEC virulence genes. In addition, these 
O63 strains all belonged to phylogroup B2 while the 
majority of the other STEC tested belonged to phylo-
group B1. There are indications that strains belong-
ing to different phylogroups have different ecological 
niches and life-history traits. Phylogroup A and B1 
strains appear to be generalists, able to occupy a 
broad range of vertebrate hosts, while B2 and D strains 
are more commonly isolated from birds and mammals 
[28]. Phylogroup B2 strains are considered to mainly 
host adapted E. coli with longer persistence in hosts 
than strains belonging to other phylogroups. In addi-
tion, phylogroup B2 generally harbour extra-intestinal 
virulence traits at higher frequency [29].
No significant difference in age distribution was found 
between stx2f STEC cases and other STEC cases. Twenty 
per cent of the Dutch stx2f STEC cases were four years 
or younger, while 79% of the German stx2f STEC cases 
reported by Prager et al. [12] were in this age group. 
The course of a stx2f STEC infection was less severe 
compared to other STEC infections, especially STEC 
O157 infections. The reason of this less severe course 
is unknown, but one could hypothesise that stx2f toxin 
is less toxic or produced in lower quantities than the 
other Shiga toxin variants. The putative presence – or 
Table 4
Risk factors as reported by the STEC cases (n=417)a and community controls (n=1,396)b, the Netherlands, 2008–2011







Contact with ill person 1/31 (3) 19/98 (19)c 24/135 (18)c NA
Contact with livestock 8/31 (26) 28/98 (29) 32/135 (24) 254/1,236 (21)
Dairy products of raw milk consumption 7/31 (23) 16/98 (16) 10/135 (7)c 285/1,320 (22)
Raw or undercooked meat consumption  12/31 (39) 52/98 (53) 53/135 (39) 545/1,386 (39)
Raw vegetables/salads consumption 23/29 (79) 71/95 (75) 95/133 (71) 1,080/1,348 (80)
Bean sprouts consumption 11/28 (39) 20/94 (21) 24/129 (19)c 301/1,338 (2)c
Travel abroad 9/57 (16) 39/182 (21) 32/178 (18) 195/1,364 (14)
NA: not available; STEC: Shiga toxin-producing Escherichia coli.
In the Table the denominators of the fractions vary because the information in question was not available from all cases or controls.
a  The number of STEC cases provided is the number of cases with information on at least one of the risk factors listed in the table available 
(417 of 549 total STEC cases).
b  The number of community controls provided is the number of controls with information on at least one of the risk factors listed in the table 
available (1,396 of 1,420 total controls).
c  Significantly different from stx2f cases (p<0.05).
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absence – of other virulence genes not determined in 
this study could also be involved. 
This is the first report of possible risk factors and 
sources for stx2f STEC. The risk factor analysis revealed 
that person-to-person transmission seems to be less 
relevant in stx2f STEC infections as compared to other 
STEC infections. However, the mild course of the infec-
tion might mask shedding (contact) persons, which 
are then not diagnosed nor reported by case patients. 
stx2f STEC cases reported eating dairy products made 
of raw milk, and bean sprouts more often than STEC 
O157 cases. 
To confirm whether stx2f STEC is partially foodborne, 
food products incriminated in our case–control study, 
or, when occurring, outbreak investigations could be 
tested for stx2f STEC. When foodborne or other non-
human stx2f STEC are found, comparison with human 
isolates of the same serotype with for example pulsed-
field gel electrophoresis (PFGE) or sequence-based 
typing techniques, could help to further elucidate 
sources and reservoirs of stx2f STEC and determine the 
genetic heterogeneity within these serotypes. Beutin 
et al. [30] tested 219 STEC strains from meat, milk and 
cheese samples for serotype and genetic variants of 
Shiga toxins in the period from 2005 to 2006. None of 
these strains tested positive for stx2f. 
Stx2f STEC was first detected in the gastrointesti-
nal tract of apparently healthy pigeons in Italy and 
Germany [4,31]. With the relative high faecal carriage of 
stx2f STEC in pigeons, ranging from six to 16%, pigeons 
were considered as a reservoir [7]. However, the pre-
sent study did not point in the direction of pigeons or 
other birds, as none of the serogroups found have been 
reported in avian species. In addition, none of the stx2f 
STEC cases reported contact with birds. It should be 
noted that as the data about risk factors were available 
for only a part (31/87; 36%) of the stx2f STEC cases, 
less strong associations might have been missed due 
to lack of power.
In conclusion, human stx2f STEC infections are more 
common than anticipated in the Netherlands, with an 
estimated 20% of all STEC infections constituting the 
stx2f gene. Stx2f STEC form a clinically and microbiologi-
cally distinct group within STEC, mostly harbouring the 
eae, but lacking the hly gene and not seen together 
with other stx genes or in STEC O157. Stx2f STEC infec-
tions appear to be relatively mild compared to other 
STEC infections, especially STEC O157. The present 
study could not confirm exposure to pigeons or other 
birds as source for infections, but alternatively found, 
although not very strong, associations with raw dairy 
products and bean sprout consumption. To further 
explore such associations, more research would be 
needed, also using additional diagnostic and typing 
methods. The trend in stx2f will be further monitored 
in the coming years and will also allow more powerful 
case–control analyses.
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